E
Ester Fonsatti
Researcher at University of Siena
Publications - 72
Citations - 4126
Ester Fonsatti is an academic researcher from University of Siena. The author has contributed to research in topics: Melanoma & Antigen. The author has an hindex of 31, co-authored 72 publications receiving 3883 citations. Previous affiliations of Ester Fonsatti include Nuclear Regulatory Commission.
Papers
More filters
Journal ArticleDOI
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Maria Colombino,Mariaelena Capone,Amelia Lissia,Antonio Cossu,Corrado Rubino,Vincenzo De Giorgi,Daniela Massi,Ester Fonsatti,Stefania Staibano,Oscar Nappi,Elena Pagani,Milena Casula,Antonella Manca,MariaCristina Sini,Renato Franco,Gerardo Botti,Corrado Caracò,Nicola Mozzillo,Paolo A. Ascierto,Giuseppe Palmieri +19 more
TL;DR: The findings about the prevalence of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful in the management of this disease.
Journal ArticleDOI
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabrò,Aldo Morra,Ester Fonsatti,Ornella Cutaia,Giovanni Amato,Diana Giannarelli,Anna Maria Di Giacomo,Riccardo Danielli,Maresa Altomonte,Luciano Mutti,Michele Maio +10 more
TL;DR: Although the effect size was small in the phase 2 trial, tremelimumab seemed to have encouraging clinical activity and an acceptable safety and tolerability profile in previously treated patients with advanced malignant mesothelioma.
Journal ArticleDOI
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Anna Maria Di Giacomo,Paolo A. Ascierto,Lorenzo Pilla,Mario Santinami,Pier Francesco Ferrucci,Diana Giannarelli,Antonella Marasco,Licia Rivoltini,Ester Simeone,Stefania Vittoria Luisa Nicoletti,Ester Fonsatti,Diego Annesi,Paola Queirolo,Alessandro Testori,Ruggero Ridolfi,Giorgio Parmiani,Michele Maio +16 more
TL;DR: The combination of ipilimumab plus fotemustine has clinical activity in patients with metastatic melanoma, including those with brain metastases, including the most common grade 3 or 4 immune-related adverse events were hepatic.
Journal ArticleDOI
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
TL;DR: Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy and the potential usefulness of CD105 in tumor imaging and antiangIogenetic therapy has been well documented utilizing different animal models.
Journal ArticleDOI
Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine
Luca Sigalotti,Elisabetta Fratta,Sandra Coral,Silvia Tanzarella,Riccardo Danielli,Francesca Colizzi,Ester Fonsatti,Catia Traversari,Maresa Altomonte,Michele Maio +9 more
TL;DR: Findings identify promoter methylation as directly responsible for the intratumoral heterogeneity of therapeutic CTA in melanoma and foresee the use of 5-AZA-dCyd to overcome the limitations set by their intratumor heterogeneous expression to CTA-based vaccine therapy.